Platelet protection in coronary artery surgery: Benefits of heparin-coated circuits and high-dose aprotinin therapy

Wendel, Hans Peter; Schulze, Hans‐Joachim; Heller, W.; Hoffmeister, Hans-Martin

doi:10.1016/s1053-0770(99)90208-2

Cited by 8 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, Wendel et al [18] in 1999, argued that high-dose Aprotinin may compete in the coating of the CPB circuit, making it more biocompatible and thus favoring the maintenance of platelet population and its viability in order to contribute to hemostasis after CPB. Moreover, the affinity of Aprotinin by proteins GPIIb/IIIa from the platelet receptor is cytoprotective, because it prevents the binding of platelets to foreign surfaces of the CPB circuit [19].…”

Section: Discussionmentioning

confidence: 99%

Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?

Ferreira¹,

Vicente²,

Évora³

et al. 2009

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass? Abstract Objective: Evaluation of the hemostatic and platelets effects in children with acyanogenic congenital heart disease undergone on-pump surgery who received aprotinin.Methods: A prospective randomized study was performed on children aged 30 days to 4 years who had undergone correction of acyanogenic congenital heart disease using cardiopulmonary bypass (CPB) and were divided into two groups: Control (n=9) and Aprotinin (n=10). In the Aprotinin Group the drug was administered before and during CPB and the hemostatic dysfunction was analyzed by clinical and biochemical markers. Differences were considered to be significant when P<0.05.Results: The groups were similar regarding demographic and intraoperative variables, except for a greater hemodilution in the Aprotinin Group. The drug presented no benefit regarding time of mechanical pulmonary ventilation, stay in the postoperative intensive care unit and hospital, or regarding the use of inotropic drugs and renal function. Platelet concentration was preserved with the use of Aprotinin, whereas thrombocytopenia occurred in the Control Group since the initiation of CPB. Blood loss 5.

show abstract

Section: Discussionmentioning

confidence: 99%

Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?

Ferreira¹,

Vicente²,

Évora³

et al. 2009

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

show abstract

Prevention of Ischemic Injury in Cardiac Surgery

Burke¹,

Verrier²

2022

Perioperative Medicine

View full text Add to dashboard Cite

Heparin coatings for improving blood compatibility of medical devices

Biran

Pond

2017

Advanced Drug Delivery Reviews

261

205

View full text Add to dashboard Cite

Blood contact with biomaterials triggers activation of multiple reactive mechanisms that can impair the performance of implantable medical devices and potentially cause serious adverse clinical events. This includes thrombosis and thromboembolic complications due to activation of platelets and the coagulation cascade, activation of the complement system, and inflammation. Numerous surface coatings have been developed to improve blood compatibility of biomaterials. For more than thirty years, the anticoagulant drug heparin has been employed as a covalently immobilized surface coating on a variety of medical devices. This review describes the fundamental principles of non-eluting heparin coatings, mechanisms of action, and clinical applications with focus on those technologies which have been commercialized. Because of its extensive publication history, there is emphasis on the CARMEDA BioActive Surface (CBAS Heparin Surface), a widely used commercialized technology for the covalent bonding of heparin.

show abstract

Platelet protection in coronary artery surgery: Benefits of heparin-coated circuits and high-dose aprotinin therapy

Cited by 8 publications

References 28 publications

Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?

Aprotinina preserva plaquetas em crianças com cardiopatia congênita acianogênica operadas com circulação extracorpórea?

Prevention of Ischemic Injury in Cardiac Surgery

Heparin coatings for improving blood compatibility of medical devices

Contact Info

Product

Resources

About